NAUT

Nautilus Biotechnolgy, Inc. (NAUT) Economic Moat Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Profitability Returns

TTM returns remain deeply negative, with ROIC at -39.5%, ROE at -37.6%, and ROA at -34.6%, indicating no evidence of durable economic profits.

Margins are severely negative across the income statement, with gross margin at -9.2% and operating margin at -330.4%, showing the business is still far from scale economics.

Scale Efficiency

Asset and capital efficiency remain extremely poor, with asset turnover at 0.0012 and fixed asset turnover at 0.0064, suggesting limited operating leverage.

Working capital is strong on a liquidity basis, but the cash conversion cycle is highly negative at -206.3 days due to elevated payables, which does not offset the weak underlying efficiency.

Balance Sheet Resilience

Liquidity remains very strong with a current ratio of 10.1 and cash ratio of 1.52, providing near-term resilience despite weak profitability.

Debt remains manageable at 0.21 debt-to-equity and net debt-to-EBITDA of -0.27, but the company still lacks earnings power to support a stronger moat view.

Valuation Support

The stock trades at a low price-to-book of 0.93 and below fair value on the provided model, but valuation support is limited by deeply negative cash flow and earnings.

Extremely high sales and cash flow multiples reflect a very small revenue base and do not indicate a durable competitive advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nautilus Biotechnolgy, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →